Biomarker Core
生物标志物核心
基本信息
- 批准号:10385837
- 负责人:
- 金额:$ 47.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAlzheimer&aposs DiseaseAlzheimer&aposs disease pathologyAlzheimer’s disease biomarkerAmyloidAmyloid beta-42Amyloid beta-ProteinAnatomyAtrophicBiological AssayBiological MarkersBlood flowBrainBrain imagingCatalogingCerebrospinal FluidCerebrovascular DisordersChargeClinicalCollaborationsCollectionCommunitiesConsultationsDataData AnalysesData SetDevelopmentDiseaseEnsureEtiologyEvaluationFutureGoalsGrantImageImpaired cognitionIndividualInflammationInfrastructureJointsLewy Body DiseaseLightLinkLiquid substanceMachine LearningMagnetic Resonance ImagingMethodsModalityMolecularNerve DegenerationNeurodegenerative DisordersNeurofibrillary TanglesNeuronal InjuryPerfusionPositron-Emission TomographyPreparationPrevention strategyProcessProcess AssessmentProtocols documentationResearchResearch DesignResearch PersonnelRiskSecureSenile PlaquesSiteStandardizationSymptomsSynapsesTechniquesTimeTracerUniversitiesVascular DiseasesWalkingWhite Matter HyperintensityWisconsinWorkalpha synucleinanalytical methodbrain healthcase controlcohortcommunity centerdensityimage processingimaging biomarkerin vivoischemic lesionneurofilamentneurograninneuroimagingneuron lossneurovascularnovelpeerpre-clinicalquality assurancerepositoryresiliencetau Proteinstheoriestoolweb-based informatics
项目摘要
PROJECT SUMMARY- BIOMARKER CORE (CORE G)
The Biomarker Core (BMC) of the Wisconsin Alzheimer's Disease Research Center (ADRC) represents the
capability and infrastructure for peering into the brain in vivo to obtain biological markers of Alzheimer's
disease (AD) and related disorders and non-disease-specific qualities characterizing brain health and
resilience. Since the pre-clinical time frame of AD is a major emphasis of the ADRC, and since it is increasingly
understood that AD pathology occurs well before its symptoms, the charge of this core is to provide the
necessary capabilities, tools, and infrastructure to investigators to characterize as accurately as possible the
early in-vivo changes of AD, effect of risk and resilience factors, and effect of prevention strategies on relevant
biomarkers. The core will focus on collecting, quality checking, and curating several types of AD-relevant
biomarkers including a) markers indicative of AD - defined by amyloid plaques and neurofibrillary tangles, and
ascertainable by molecular PET imaging or cerebrospinal fluid (CSF) assays; b) markers of cerebrovascular
diseases - the second most common etiology (or etiologies) of cognitive decline and ascertainable by new MRI
methods; c) markers of other neurodegenerative diseases as they become available via CSF or PET; and d)
markers of general brain health including synaptic density, neuronal injury, atrophy, connectivity, inflammation,
and blood flow that are possible through PET, MRI and CSF modalities. To meet these goals, we will
accomplish the following aims: Aim 1: Obtain biological markers of AD's hallmark neuropathological features -
amyloid plaques and neurofibrillary tangles with CSF and/or molecular PET imaging. Aim 2: Collect biomarkers
of concomitant features, such as vascular disease, inflammation, and neuronal death. Aim 3: Develop method
for interpreting biomarker readouts, particularly for Amyloid (A), tau (T) and neurodegeneration (N). Aim 4:
Support ADRC investigators with infrastructure and analytic support. Aim 5: Share images, fluid, and derived
data with the National Alzheimer's Coordinating Center (NACC), local investigators, and other qualified
investigators throughout the world. Aim 6: Expand the Center's biomarker capability, including a) adopting new
methods and modalities in this fast-changing field, and b) for harmonizing previously collected data or multi-site
data with current or future collection methods. The BMC will work interactively with the other ADRC cores to
serve the needs of the ADRC investigators as efficiently as possible and deliver high quality data to NACC and
other users so we, as a field, can come to answers faster in detecting and intervening effectively in AD.
项目总结-生物标志物核心(core g)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sterling C Johnson其他文献
Sterling C Johnson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sterling C Johnson', 18)}}的其他基金
Wisconsin Registry for Alzheimer's Prevention
威斯康星州阿尔茨海默病预防登记处
- 批准号:
10655978 - 财政年份:2023
- 资助金额:
$ 47.89万 - 项目类别:
Integrative Pathways to Cognitive, Affective, and Brain Health
认知、情感和大脑健康的综合途径
- 批准号:
10558956 - 财政年份:2022
- 资助金额:
$ 47.89万 - 项目类别:
Integrative Pathways to Cognitive, Affective, and Brain Health
认知、情感和大脑健康的综合途径
- 批准号:
10707362 - 财政年份:2022
- 资助金额:
$ 47.89万 - 项目类别:
Manifold-valued statistical models for longitudinal morphometic analysis in preclinical Alzheimer's disease (AD)
用于临床前阿尔茨海默病 (AD) 纵向形态分析的流形值统计模型
- 批准号:
9170619 - 财政年份:2016
- 资助金额:
$ 47.89万 - 项目类别:
Wisconsin Registry for Alzheimer's Prevention: Sex Differences in DNA Methylation
威斯康星州阿尔茨海默病预防登记处:DNA 甲基化的性别差异
- 批准号:
9236948 - 财政年份:2016
- 资助金额:
$ 47.89万 - 项目类别:
The Effect of Calorie Restriction on Brain Aging
热量限制对大脑衰老的影响
- 批准号:
8513225 - 财政年份:2012
- 资助金额:
$ 47.89万 - 项目类别:
The Effect of Calorie Restriction on Brain Aging
热量限制对大脑衰老的影响
- 批准号:
8383292 - 财政年份:2012
- 资助金额:
$ 47.89万 - 项目类别:
The Effect of Calorie Restriction on Brain Aging
热量限制对大脑衰老的影响
- 批准号:
8704847 - 财政年份:2012
- 资助金额:
$ 47.89万 - 项目类别:
Posterior Cingulate Perfusion and Alzheimer Disease Risk
后扣带回灌注与阿尔茨海默病风险
- 批准号:
8195978 - 财政年份:2009
- 资助金额:
$ 47.89万 - 项目类别:














{{item.name}}会员




